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Abstract Regulation of sterol biosynthesis in the terminal 
portion of the pathway represents an efficient mechanism by 
which the cell can control the production of sterol without 
disturbing the production of other essential mevaionate pathway 
products. We demonstrate that mutations affecting early and late 
steps in sterol homeostasis modulate the expression of the ERG3 
gene: a late step in sterol biosynthesis in yeast. Expression of 
ERG3 is increased in response to a mutation in the major isoform 
of HMG CoA reductase which catalyzes the rate-limiting step of 
sterol biosynthesis. Likewise, mutations in non-auxotrophic 
ergosterol biosynthetic genes downstream of squalene production 
(erg2, erg3, erg4, ergS, and ergO') result in an up-regulation of 
ERG3 expression. Deletion analysis of the ERG3 promoter 
identified two upstream activation sequences: UAS1, which when 
deleted reduces ERG3 gene expression 3-4-fuld but maintains 
sterol regulation and UAS2, which when deleted further reduces 
ERG3 expression and abolishes sterol regulation. The recent 
isolation of two yeast genes responsible for the esterification of 
intracellular sterol (ARE1 and ARE2) has enabled us to directly 
analyze the relationship between sterol esterification and de novo 
biosynthesis. Our results demonstrate that the absence of sterol 
esterification leads to a decrease in total intracellular sterol and 
ERG3 is a target of this negative regulation. 
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1. Introduction 
Sterols are essential cellular molecules which function to 
regulate membrane fluidity, permeability, the activity of mem- 
brane-bound enzymes and growth rate. Ergosterol (ergosta- 
5 7,22-trien-313-ol) is the predominant fungal sterol and the 
btosynthetic pathway leading to its formation is now well 
d~::fined (see [1] for review). However, the regulation of sterol 
biosynthesis, within the post-squalene portion of the pathway, 
has received little attention. 
The ERG3 gene in yeast encodes a C-5 sterol desaturase 
hich introduces a AS-bond in the B-ring of ergosterol. C-5 
sl erol desaturase is a multicomponent enzyme system which is 
cyanide sensitive, requires iron and molecular oxygen for ac- 
tiAty and is coupled to the NAD(P)H-cytochrome 
b/cytochrome b5 reductase microsomal electron transport 
s~,stem [2]. This enzymatic activity has been conserved 
tt roughout evolution as demonstrated by the presence of C- 
5 sterols in all organisms from the fungal, plant and animal 
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kingdoms. We have shown previously by gene-disruption that 
ERG3 is non-essential for the aerobic viability of Saccharo- 
myces cerevisiae [3]. Haploid yeast cells harboring a null allele 
of ERG3 accumulate the sterol intermediate episterol (ergosta- 
7,22-dien-3~-ol) which can functionally substitute for ergo- 
sterol in the membrane. Although the mutant does not require 
the addition of exogenous terol for viability, it does exhibit 
reduced growth rate, decreased transformation efficiencies and 
increased permeability to cations such as Ca 2+ [4]. While we 
have shown ERG3 to be non-essential in an otherwise wild- 
type background, Smith and Parks [5] have demonstrated that 
ERG3 is essential in a heme-deficient background. In another 
report, Nes and Dhanuka [6] have shown that sterol molecules 
containing a AS-bond or having the capability of being con- 
verted to a A 5 sterol regulate the ability of a hem3 erg12 
double mutant (GL7) to synthesize rgosterol. These observa- 
tions suggest hat ERG3 may be a regulatory target for sterol 
biosynthesis n the terminal portion of the ergosterol biosyn- 
thetic pathway. 
In the present study, we examine the transcriptional regula- 
tion of ERG3 by expression of the Escherichia coli lacZ gene, 
under the control of the ERG3 promoter, in wild-type and 
mutant strains of S. cerevisiae. We show that ERG3 is subject 
to regulation by mutations in the ergosterol biosynthetic path- 
way which alter intracellular sterol composition; and by mu- 
tations in the ARE genes which alter the ratio of free to 
esterified sterol. In addition, we identify by deletion promoter 
analysis two cis-acting regulatory regions present in the ERG3 
promoter, one which mediates activation of the ERG3 gene 
under normal growth conditions and a second region of the 
ERG3 promoter which is partially required for ERG3 up-reg- 
ulation in response to a block in the ergosterol biosynthetic 
pathway. 
2. Materials and methods 
2.1. Strains, growth conditions, and transformation methods 
The wild-type yeast strain, BWG1-7a (MATa adel-lO0 his4-519 
leu2-112 ura3-52), was provided by Dr. L. Guarente, Massachusetts 
Institute of Technology, and used to create a panel of ergosterol 
biosynthetic mutants, erg2 (C-8 sterol isomerase), erg3 (C-5 sterol 
desaturase), erg4 (C-24 sterol reductase), erg5 (C-22 sterol desaturase), 
and erg6 (C-24 sterol methyltransferase) disrupted with the LEU2 
gene by the one-step gene disruption technique of Rothstein [7] and 
verified by sterol analysis. J. Rine provided JRY527 (MATa ura3 52 
his3A200 ade2 101 lys2 801 met-) and the isogenic HMG CoA 
reductase mutants JRY1159 (hmgl : :L YS2) and JRY1160 
(hmg2.':HIS3). Yeast wild-type and are mutants, disrupted at one 
or both ARE genes: ARE1 ARE2 (MATa his3-11 his3-15 1eu2-3,112 
trpl-1 ura3-1 kanl-lO0), arelare2 (MATot his3-11 his3-15 leu2-3,112 
trpl-1 ura3-1 kanl-lO0 ade2-1 met14A arel : :HIS3 are2: :LEU2), 
ARElare2 (MATt~ his3-11 his3-15 leu2-3,112 trpl-1 ura3-1 kanl-lO0 
met14A are2::LEU2), and arelARE2 (MATa his3-11 his3-15 1eu2- 
3,112 trpl-1 ura3-1 kanl-lO0 ade2-1 arel:.'H1S3) were used to study 
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the effect of sterol esterification on ERG3 expression. Yeast were 
grown in YEP medium containing 2% glucose (YEPD) [8]. Selective 
media containing 2% glucose (SC) were based upon synthetic om- 
plete medium as described by Sherman et al. [8] with appropriate 
nutrients omitted where required to maintain plasmid selection. 
Yeast strains were transformed using the lithium/cesium acetate 
method as described previously [9]. K coli (DH5~x) was transformed 
as described previously [10]. 
2.2. Construction of ERG3 promoter-lacZ fusion gene 
The ERG3 promoter was amplified by PCR using plU304 as tem- 
plate DNA and sequence specific PCR primers, MB4 (5' 
GGGGGGATCCATATCTCAAATCTAGACGAAT 3') and MB5 
(5' GGGGGGAATTCTCCCCTCGAGGTCCTGCTTTGAGTCG 
3'). MB4 contains a BamHI restriction enzyme recognition sequence 
and MB5 contains an EcoRI restriction enzyme recognition sequence 
to facilitate subcloning of the amplified DNA at the BamHl and 
EcoRI sites of the lacZ containing vector, pYLZ-6 [1 I], to yield 
plU565, pYLZ-6 contains the lacZ gene lacking the first eight coding 
amino acids adjacent to a MCS allowing for insertion of promoter 
fragments o drive expression of lacZ. PCR primers were designed to 
amplify 891 base pairs of the ERG3 promoter and the ERG3 initiation 
codon only. No other ERG3 coding amino acids were included in the 
fusion. 
Deletion mutants of plU565 were created either using naturally 
occurring restriction enzyme sites within the ERG3 promoter or by 
PCR (see Fig. 1). plU567 is deleted for one of the Sinai sites and the 
18 bp between the two SmaI sites, plU572 contains a 521 bp XhoI- 
SmaI deletion of the ERG3 promoter and plU573 contains a 385 bp 
SmaI-XbaI deletion of the ERG3 promoter. PCR was used to generate 
a set of five nested eletion mutants which possessed i entical 3' ends 
(and thus were identical at the ERG3promoter-lacZ fusion junction) 
and varied at the 5' ends only. The 3' PCR primer (MB4) remained 
constant in each PCR reaction and different 5' primers were used to 
create various end-points, plU304 was used as template DNA for all 
PCR reactions ( ee Fig. 1 for position of PCR primers). MB4 contains 
the BamHI restriction enzyme recognition sequence and each of the 5' 
primers contains the EcoRI restriction enzyme recognition sequence, 
to facilitate subcloning of the amplified DNA into the MCS of pYLZ- 
6. The authenticity of each PCR product was verified by DNA se- 
quencing using the Sequenase 2.0 DNA sequencing kit from USB and 
sequencing primers, YLZ6-1 (5' CAATACGCAAACCGCCTG 3') 
and YLZ6-2 (5' AGGCGATFAAGTTGGGTA 3') which are homo- 
logous to pYLZ-6 vector sequences flanking the ERG3 promoter in- 
sert. 
2.3. ~-Galactosidase enzyme assay 
Following transformation of an appropriate yeast strain with an 
ERG3promoter-lacZ fusion plasmid, two randomly picked transfor- 
mants were grown overnight in SC medium lacking uracil to maintain 
plasmid selection. Cultures were harvested at an OD660 of 0.85-1.0. [3- 
Galactosidase enzyme assays were performed on cell extracts as de- 
MS5 
-891 TCCCCTCGAGGTCCTGCTTTGAGTCGTTTTCAGCCCACTCAGCATCTCTTCGTCTCCTCCT -831 
-769 GAAAAAAAAAAAAAC TGAGC CTTTAGTACAC TACAGTTAC TGCTACAGC CTTTTACAGC C C -709 
-708 AGCATCTGGCACCACTACGCTATAATATATGATGCGTCTATTATGCTAGAATCCTTCCTGA -648 
- 647 AAGGGCATTCTGGAAGC  C TACGTAC AGAGTGACAATATATTA~ATC CATAAAAATAG -587 
- 586 ATTAGCX~CAGC TCTGCCATT TTTTTCATAOC C GAAAGAAGAAAAA CTGAAAAAAAAAATGA -526 
-525 TACGAAAAAACCGCGAAACGACGCCTTTTGTTGCGATTGTCGOGCATCGCAAGTTACGACG -465 
-464CGTTGTCCCTTGCATCGCTGC GTGTGGCACGAC CACTGCGGCC TAAACGAC CGAGATCG -404 
p~399 ~_ 
-403 GTGGCCCC-OGGCA-GACCACCCGAAAACTCCCGGGCATTATTTCGGTCGTTTAGTTGCGCCC -343 
Sinai pA321 Sinai ~_  OA995 
-342 CAGGGCAAC C~TGTATAC GAGOC CGATGGC TGC~ATAAAC GAAAAATTC AGC42 TCGTA -282 
p~271 
-281 TAAGTGGCACAA TAGAAGGTGAAGAAG~AACAGCAGGTGCATTGAAACAAGAGGTTC AGCAG -221 
-220 CGATCGGGTATTGTTGTTGCTGCTATTATGTAACGGTCGAAAGAAACATCGCGGTATATAT - 160 
- 159 TAGAGGCGGGATTTCTATCTTTCTTATCAATTCTTTTTTCATTCACTTGTTCATTCATTCT -99 
-98 TTACATT TGTC TTGTTCTT TGAAGTGGTTGCAGAGGAGGTCAG TTTGTTGCA TT TGTAAAA -38 
-37 AAAGATAATAAGAAAAATATTC GTC TAGATTTGAGATA~'O 
Xbal +l 
Fig. 1. Sequence of the ERG3 promoter including the initiation co- 
don (indicated in bold) and 891 bp upstream. PCR primers used to 
amplify segments of the promoter are indicated by arrows and 
named for the deletion end-point created. The actual sequence of 
MB4 is the complement of the sequenced overlined. 
scribed in [8]. Each ERG3promoter-lacZ fusion construct was assayed 
in two separate transformants, in duplicate, over 3 days. Values re- 
ported are the average of three assays along with the standard evia- 
tion. A gcn4-lacZ fusion gene [12] was used as a control to verify that 
the regulatory effect was specific for ERG3. 
2.4. Quantitative stero! analysis 
Total sterols were extracted as described by Mohahn and Woods 
[13]. Sterols were separated on a Hewlett-Packard 5890 series II gas 
chromatograph (GC) with a capillary column (Hewlett Packard-HP5) 
of 15 m x 0.25 mm x 0.25 pm film thickness programmed from 195 to 
300°C. The initial temperature was 3 min at 195°C, then an increase at 
5.5°C/min until the final temperature was reached and held for 4 min. 
The linear velocity was 30 cm/s using nitrogen as the carrier gas and 
injections were run in the splitless mode. 1 I11 of sample dissolved in 
heptane was injected and the sterol composition was determined based 
on retention times relative to retention times of known standards. To 
calculate the percentage of sterol per mg of cell mass, 10 ml of the 
original culture was harvested by vacuum filtration onto a pre- 
weighed 0.45 pm Whatman filter. The cells were dried in a 75°C 
oven overnight, followed by desiccation at room temperature for 
4 h. Weight of the cells was taken immediately upon opening the 
desiccator. The amount of each individual sterol was calculated based 
on the area under each peak of the chromatograph relative to a 
Table 1 
Expression of the ERG3-lacZ fusion gene in an ergosterol biosynthetic mutant background 
Genotype a ~-Galactosidase activity 
ERG3-1acZ (plU565) Ratio of erg mutant/WT gcn4-lacZ b (p180) Ratio of erg mutant/WT 
BWG1-7a  (wt) 123 + 22 1.0 33 + 4.7 1.0 
erg6 315 + 75 2.6 35 + 3.8 1.06 
erg2 713 + 56 5.8 19 + 5.0 0.58 
erg3 770+ 112 6.3 21 + 2.0 0.64 
erg5 627 + 78 5.1 21 + 3.2 0.64 
erg4 274+ 16 2.2 35 + 6.0 1.06 
JRY527 (wt) 66 + 17 1.0 100 + 37 1.0 
hmgl 284 + 45 4.3 99 + 9.0 0.99 
hmg2 67 + 1 1.0 130 + 30 1.3 
Quantitation of [~-galactosidase enzyme activity from the ERG3promoter-lacZ fusion was carried out as described in Section 2. [~-Galactosidase 
activity is nmol ONPG hydrolyzed/min per mg protein and is the average of values obtained from two independent transformants a sayed in 
duplicate over 3 days. 
~BWG1-7a, erg2, erg3, erg4, erg5, and erg6 mutants are isogenic strains. JRY527, hmgl, and hmg2 are isogenic strains. HMG1 encodes the major 
isoform of HMG CoA reductase in yeast contributing 83% of enzymatic activity in a vegetatively growing cell [16]. 
bgcn4-lacZ serves as a control to verify that the regulatory effect is specific to ERG3. 
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Plasmid Deletion 
name end point Yhm Smal SmaI XbaI ATG 
-1 BWG1-7a 
plU565 -891 123 +/- 22 
B-galaetosidase Activity 
Ratio of Ratio of 
erg2 mutant/WT JR527 hmglHMG2 mutant/WT 
713+/-56 5.8 61+/-12 284+/-45 4.7 
163 
p-A399 -399 I tx\,~ I 104 +/- 21 
plU567 -397 -373 I. I r , . \ \ l  I 142 +/-27 
plU572 -397 - 11 t ] [] 9 +/- 0.2 
plU573 -885 -373 ["'7 k'-.-,.xa I 188 +/- 40 
p-A373 -373 t \ \ " l  I 148 +/- 35 
p-A321 -321 / " - -  ] 52 +/- 9 
p-A295 -295 • I 33 +/- 5 
p-A271 -271 L . . . .~ I  26 +/- 6 
pYLZ-6 5 +/- 0.2 
363 +/- 77 7.0 25 +/- 8.0 104 +/- 28 4.2 
43 +/- 11 1.6 23 +/- 4.0 32 +/- 6.0 1.4 
l::g. 2. Deletion analysis of the ERG3 promoter. ~-Galactosidase enzyme activity was quantitated from ERG3 promoter deletion mutants which 
~.~re fused to lacZ, and transformed into the wild-type yeast strains, BWG1-7a and JRY527, and two ergosterol biosynthetic mutants, blocked 
a erg2 and hmgl. Specifc activity is nmol ONPG hydrolyzed/min per mg protein and is the average of two independent transformants a sayed 
ii duplicate over 3 days. 
kaown amount of sterol standard loaded onto the GC using the 
Iqewlett-Packard sterol quantitation program. Each sample was in- 
jc=ted twice and the values averaged. 
3 Results and discussion 
3 1. A block in the ergosterol biosynthetic pathway up-regulates 
ERG3 expression 
Thus far, regulation of ergosterol biosynthesis has focused 
e a enzymatic steps in the pre-lanosterol portion of the path- 
x~ ay. Casey et al. [14] have presented evidence for the ability 
c f ergosterol to regulate its own biosynthesis via a negative 
f~edback mechanism. However, the exact nature of this reg- 
t latory mechanism was not clear. We were interested in de- 
t~rmining whether or not a block in the ergosterol biosyn- 
tiletic pathway would effect the expression of ERG3. To 
e ~amine this, a panel of isogenic ergosterol biosynthetic mu- 
tmts was transformed with plU565 (wild-type ERG3 promo- 
t~r-lacZ fusion gene) and assayed for [I-galactosidase activity 
t,nder aerobic growth conditions. The results presented in 
~I able 1 illustrate that a block in the ergosterol biosynthetic 
l,athway results in an increase in ERG3 expression. Interest- 
iagly, each ergosterol mutation results in a different degree of 
ERG3 up-regulation, suggesting that the cell is capable of 
modulating the degree of ERG3 activation in response to 
the accumulation of distinct sterol intermediates. Mutations 
in erg2 and erg3 both result in a 6-fold increase in ERG3 
expression. The erg2 mutation in S. cerevisiae is non-auxo- 
trophic for sterol and results in an accumulation of sterol 
intermediates such as ergosta-5,8,22-313-ol, and ergosta-8-en- 
313-ol [15] and the erg3 mutation leads to an accumulation of 
ergosta-7,22-dien-313-ol [3]. Similarly, a mutation in the 
HMG1 gene encoding the major isoform of HMG-CoA re- 
ductase [16] results in a 4-fold increase in ERG3 expression. 
Loss of the HMG2 gene results in no increase in ERG3 
expression, hmgl and hmg2 mutants show a 50 and 20% de- 
crease, respectively, in end product ergosterol (data not 
shown). These decreases are not sufficient o result in an er- 
gosterol requiring phenotype and furthermore, more than half 
of cellular ergosterol is stored as esters in microlipid droplets. 
3.2. The ERG3 promoter contains at least one UAS required 
for regulated expression of ERG3 
To identify cis-acting sequences necessary for regulated ex- 
pression of ERG3, a series of ERG3 promoter-deletion mu- 
tants was created and fused to lacZ. B-Galactosidase enzyme 
q able 2 
~ mantitation of 13-galactosidase enzyme activity from the ERG3promoter-lacZ fusion gene in sterol esterification mutant backgrounds 
I ;enotype ~ ]3-Galactosidase activity 
ERG3-lacZ Ratio of mutant/wt gcn4-lacZ b Ratio of mutant/wt 
~Vild-type 85 + 25 1.0 15 _+ 0.7 1.0 
,,el/are2 31 + 9.2 0.35 33 + 2.1 2.2 
• RE1/are2 49 + 11 0.53 14 + 2.1 0.9 
crel/ARE2 89 + 22 0.98 33 + 4.2 2.2 
Ouantitation of I~-galactosidase enzyme activity from the ERG3promoter-lacZ fusion was carried out as described in Section 2. [3-Galactosidase 
~ ctivity is nmol ONPG hydrolyzed/min per mg protein and is the average of values obtained from two independent transformants assayed in 
duplicate over 3 days. 
" M1 four strains are isogenic except at the specific ARE locus indicated. 
]?he gcn4-lacZ fusion gene served as a control to verify that the esterification effect was specific to ERG3. 
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Table 3 
Determination of the percentage of each sterol present within the 
total intracellular sterol fraction 
Genotype % total cellular sterol represented by ergosterol 
and nonergosterol intermediates 
Erg Lano Zymo Feco Epi 
AREIARE2 55.0 1.6 15.0 11.0 14.5 
arelare2 86.6 0.7 0.0 0.75 8.9 
arelARE2 67.0 1.6 12.0 4.1 12.0 
ARElare2 66.0 0.7 13.4 9.0 9.0 
aValues represent the percentage of the total sterol pool represented 
by each individual sterol. Each experiment was repeated three times 
and the data presented is of a typical experiment. Erg, ergosterol; 
Lano, lanosterol; Zymo, zymosterol; Feco, fecosterol; Epi, episterol. 
activity generated from the mutant promoters was compared 
to that of the wild-type ERG3 promoter-lacZ fusion, in the 
wild-type yeast strain. Each fusion plasmid was transformed 
separately into BWG1-7a and transformants were grown for 
maximal expression, i.e. in SC-uracil medium (for plasmid 
maintenance), high aeration and to log phase of growth. Ana- 
lysis of I]-galactosidase activity from the ERG3 promoter-lacZ 
deletion mutants, in the ergosterol biosynthetic mutants, erg2 
and hmgl, compared to their isogenic wild-type strains, 
BWG1-7a and JRY527, respectively, revealed a cis-acting re- 
gion, UAS1, which is necessary for full up-regulation of ERG3 
in response to a block in the ergosterol pathway (Fig. 2). 
Deletion of UAS1 (located between -373 and -321 nt up- 
stream of the ERG3 initiation codon) causes a 2-3-fold de- 
crease in [3-galactosidase enzyme activity in a wild-type strain 
but sterol regulation is maintained (expression of ERG3 in 
erg2 and hmgl strains with UAS1 deleted is still 4-7-fold 
greater than in ERG2 and HMG1 strains (Fig. 2)). A second 
upstream activation site, UAS2, defined as a deletion of 50 nt 
downstream of UAS1, results in a further reduction in ERG3 
expression, 2-8-fold (depending upon genetic background) 
and deletion of this UAS eliminates terol regulation. 
3.3. A disruption of the sterol esterification genes, ARE1 and 
ARE2, results in a decrease in ERG3 expression 
Intracellular sterol can exist in two forms, either free, or as 
esters, conjugated to long chain fatty acids. Steryl esters are 
the storage form of sterol while free sterols are available to be 
incorporated into the plasma membrane, their principle site of 
action. These two pools are interchangeable and regulation of 
the interconversion is required to maintain the essential 
amount of free sterol [17]. The esterification of intracellular 
sterols in all mammalian species is mediated by acyl-CoA:- 
cholesterol acyltransferase (ACAT), a membrane-bound en- 
zyme which is dependent on acyl-CoA as a fatty acid donor 
[18]. Yang et al. [19] have recently identified two yeast genes, 
ACAT related enzyme 1 (ARE1) and ACAT related enzyme 2 
(ARE2) required for esterification of intracellular sterols in 
yeast. ARE2 encodes the major isozyme and is responsible 
for the majority of sterol esterification i a vegetatively grow- 
ing cell. Disruption of both ARE1 and ARE2 results in a 
viable cell with no detectable sterified sterol. In addition, 
Yang et al. [19] have shown that the inability to esterify in- 
tracellular sterols down-regulates the sterol biosynthetic path- 
way as determined by [14C]acetate incorporation i to the lipid 
pool. To determine if ERG3 is a target of down-regulation, we 
assayed for 13-galactosidase activity in the ARE wild-type and 
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are mutant strains transformed with plU565. The results, pre- 
sented in Table 2, indicate that ERG3 expression is down- 
regulated 3-fold in the absence of intracellular sterol esterifi- 
cation (arelare2). There is a more modest decrease (1.9-fold) 
in ERG3 expression in the absence of the major ARE gene, 
ARE2, and no significant difference in ERG3 expression i  the 
absence of the minor isoform, Arelp, compared to wild-type 
cells. 
3.4. In the absence of sterol esterification, the concentration of 
intracellular sterol is decreased 
We have shown that ERG3 expression is decreased in the 
absence of sterol esterification. Based on this observation, we 
were interested in quantifying the amount of intracellular ster- 
ol present in the are mutants compared to the isogenic wild- 
type strain. Results indicated that the arelare2 double mutant 
accumulates 33% less total sterol per mg of dry cell weight 
than a wild-type cell. This result is consistent with a down- 
regulation of the sterol biosynthetic pathway. The inability of 
the cell to esterify excess sterol implies that the cell must 
down-regulate endogenous synthesis to maintain the critical 
low level of free sterol. We then considered the ratio of ergo- 
sterol to ergosterol intermediates, based on the gas-chromato- 
graphic (GC) separation, and found that the arelare2 double 
mutant possessed the greatest ratio of ergosterol to intermedi- 
ates compared to the wild-type strain or either single mutant 
(see Table 3). A plausible xplanation for this finding is that 
the absence of sterol esterification renders all intermediates 
accessible to the sterol biosynthetic enzymes and thus com- 
plete conversion to ergosterol is not prevented. 
In summary, we have shown that ERG3 expression is up- 
regulated in response to a block in the ergosterol biosynthetic 
pathway (i.e. erg2, erg3, erg5) or a decrease in end-product 
sterol due to a mutation in the major HMG-CoA reductase 
encoding gene, HMG1. We also demonstrate that ERG3 ex- 
pression is down-regulated in the absence of esterification and 
provides the first evidence for direct transcriptional regulation 
of a late sterol biosynthetic gene in response to sterol ester- 
ification defects. 
These results support the involvement of a sterol sensor 
which is capable of first detecting the absence of ergosterol 
and/or the presence of sterol intermediates within the mem- 
brane, and second, detecting the level of free ergosterol and 
mediating the regulation of de novo ergosterol synthesis to 
maintain a critical concentration of free sterol. These results 
also suggest that in mammalian cells, enzymatic steps distal to 
squalene, currently undefined at the molecular level, will very 
probably play an important role in cholesterol regulation. 
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